As VEGF-D was the most sensitive and specific diagnostic marker we examined whether measurement of serum VEGF-D could reduce the need for lung biopsy in patients with suspected LAM and how VEGF-D measurement contributed to diagnosis as defined by the recent ERS criteria. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.